MoonLake Immunotherapeutics (MLTX) News Today $12.29 +0.36 (+3.03%) As of 11:30 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest MoonLake Immunotherapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done MoonLake Immunotherapeutics (MLTX) Expected to Announce Quarterly Earnings on Wednesday4 hours ago | marketbeat.comMoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View HoldsOctober 25 at 8:02 AM | finance.yahoo.comMoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet QuestionsOctober 24, 2026 | finance.yahoo.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Has Average Target Price of $28.50October 24, 2026 | americanbankingnews.comMoonLake Immunotherapeutics (MLTX) - What Are Investment Firms Saying About This Stock?October 24, 2026 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6.4% - Here's WhyOctober 23, 2026 | marketbeat.comStock Traders Purchase High Volume of MoonLake Immunotherapeutics Call Options (NASDAQ:MLTX)October 23, 2026 | americanbankingnews.comWhat's Going On with MoonLake Immunotherapeutics Stock on Thursday?October 22, 2026 | benzinga.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Sees Heavy Call Option BuyingOctober 21, 2026 | marketbeat.comMoonLake: Downgrading To Hold As FDA Priority Review Decision RemainsOctober 20, 2026 | seekingalpha.comMoonLake’s sonelokimab faces regulatory, commercial tests, RBC saysOctober 18, 2026 | msn.comMoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC SaysOctober 16, 2026 | finance.yahoo.comMoonLake Immunotherapeutics (MLTX) Receives a Rating Update from a Top AnalystOctober 8, 2026 | theglobeandmail.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Buy Rating at HC WainwrightOctober 5, 2026 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX) and Liquidia Technologies (LQDA)October 2, 2026 | theglobeandmail.comMoonLake files FDA application for sonelokimab therapySeptember 30, 2026 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rated "Moderate Buy" by Sell-Side AnalystsSeptember 29, 2026 | marketbeat.comMLTX stock on track for worst week since last fall as FDA filing date for skin disease drug draws nearSeptember 11, 2026 | msn.comMoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical SupremacySeptember 8, 2026 | seekingalpha.comMoonLake Immunotherapeutics (MLTX)August 23, 2026 | finance.yahoo.comMoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’August 11, 2026 | msn.comMoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical GoalsAugust 10, 2026 | finance.yahoo.comMoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...August 10, 2026 | markets.businessinsider.comMoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage StudyAugust 10, 2026 | benzinga.comMoonLake's psoriatic arthritis drug meets key goals in late-stage trialAugust 10, 2026 | reuters.comMoonLake announces positive Phase 3 psoriatic arthritis resultsAugust 10, 2026 | tipranks.comMoonLake reports positive Phase 3 PsA data and $537 million cashAugust 10, 2026 | quiverquant.comQMoonLake Immunotherapeutics GAAP EPS of -$0.84August 10, 2026 | seekingalpha.comMLTX stock under pressure as investors await psoriatic arthritis trial dataAugust 3, 2026 | msn.comKristian Reich Sells 1,100 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) StockJuly 30, 2026 | insidertrades.comKristian Reich Sells 43,700 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) StockJuly 29, 2026 | insidertrades.comMoonlake Immunotherapeutics Share Price (MLTX.US)July 15, 2026 | lse.co.ukDa Silva Jorge Santos Sells 33,936 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) StockJuly 14, 2026 | insidertrades.comSLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff NearsJuly 12, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Class AJuly 11, 2026 | edition.cnn.comMoonLake Immunotherapeutics' CFO Sells 39K SharesJuly 3, 2026 | finance.yahoo.comMoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $956,933.25 in StockJuly 3, 2026 | insidertrades.comMoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis SuppurativaJune 30, 2026 | finance.yahoo.comMoonLake Immunotherapeutics - Ordinary Shares - Class AJune 26, 2026 | money.usnews.comMoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label ExpansionJune 26, 2026 | seekingalpha.comHow Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On OfferingJune 25, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Announces $200 Million Public OfferingJune 25, 2026 | tipranks.comGuggenheim Remains a Buy on MoonLake Immunotherapeutics (MLTX)June 24, 2026 | theglobeandmail.comWhy MoonLake Immunotherapeutics Stock Wilted on WednesdayJune 24, 2026 | fool.comWhy MoonLake Immunotherapeutics Stock Wilted on WednesdayJune 24, 2026 | fool.comMLTX stock extends pullback after biggest rally in over 6 months following skin disease trial data — a look at the latest developmentJune 24, 2026 | msn.comMoonLake Immunotherapeutics Prices $200 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsJune 23, 2026 | quiverquant.comQMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingJune 23, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingJune 23, 2026 | globenewswire.comMoonLake Immunotherapeutics: Label Upside Drives The Next Leg HigherJune 23, 2026 | seekingalpha.com MoonLake Immunotherapeutics Media Mentions By Week MoonLake Immunotherapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼0.590.69▲Average Healthcare News Sentiment MoonLake Immunotherapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼109▲MLTX Articles Average Week MoonLake Immunotherapeutics Trends on MarketBeatThis week vs. last weekNew Followers1Searches1Page Views3,008-12% Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies XENE News Today ACAD News Today VKTX News Today PBLS News Today AMLX News Today IDYA News Today RCUS News Today DYN News Today DNLI News Today IRON News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for MoonLake Immunotherapeutics dated 10/28/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
